{"id":"degludec","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide, one of the components of XULTOPHY 100/3.6, causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether XULTOPHY 100/3.6 causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nasopharyngitis","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Increased Lipase","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Upper respiratory tract infection","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Hypoglycemia with glucose <54 mg/dL","drugRate":"27.6%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Severe Hypoglycemia","drugRate":"0.7%","severity":"serious"},{"effect":"Severe Gastrointestinal Adverse Reactions","drugRate":"0.8%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL2107869","moleculeType":"Protein"},"aliases":["Tresiba"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"21335fe4-d395-4501-ac2a-2f20d7520da9","title":"XULTOPHY 100/3.6 (INSULIN DEGLUDEC AND LIRAGLUTIDE) INJECTION, SOLUTION [NOVO NORDISK]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-27T23:44:11.400Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06945406","phase":"PHASE1","title":"A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-16","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":124},{"nctId":"NCT06111508","phase":"NA","title":"The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2023-11-29","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT07215312","phase":"PHASE2","title":"A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-13","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT07387003","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-03-20","conditions":"Type 2 Diabetes (T2DM)","enrollment":300},{"nctId":"NCT07376200","phase":"PHASE1","title":"Single-ascending Dose Study of HEC-151 Injection","status":"NOT_YET_RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2026-03-11","conditions":"Healthy Adult Male","enrollment":81},{"nctId":"NCT06280703","phase":"PHASE1","title":"A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-05-15","conditions":"Healthy, Type 1 Diabetes Mellitus","enrollment":118},{"nctId":"NCT06153537","phase":"","title":"A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-11-29","conditions":"Diabetes Mellitus, Type 2","enrollment":179},{"nctId":"NCT04952779","phase":"","title":"Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-06-02","conditions":"Diabetes Mellitus, Type 2","enrollment":750},{"nctId":"NCT05069545","phase":"","title":"A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-10-11","conditions":"Diabetes Mellitus, Type 1","enrollment":411},{"nctId":"NCT04770532","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-05","conditions":"Diabetes Mellitus, Type 2","enrollment":526},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT04848480","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-30","conditions":"Diabetes Mellitus, Type 1","enrollment":582},{"nctId":"NCT04588259","phase":"PHASE3","title":"Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT05417841","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2023-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":218},{"nctId":"NCT06767748","phase":"PHASE3","title":"A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-15","conditions":"Diabetes","enrollment":620},{"nctId":"NCT07242664","phase":"PHASE1","title":"Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-10-13","conditions":"Type 1 Diabetes Mellitis","enrollment":12},{"nctId":"NCT07018453","phase":"PHASE2","title":"A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-07-16","conditions":"Type 2 Diabetes Mellitus","enrollment":173},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT06685185","phase":"PHASE1","title":"A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-11-12","conditions":"Diabetes Mellitus, Type 1","enrollment":154},{"nctId":"NCT07032688","phase":"PHASE1","title":"A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-08-11","conditions":"Type 2 Diabetes","enrollment":55},{"nctId":"NCT05552859","phase":"PHASE4","title":"Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-12-05","conditions":"Type 2 Diabetes Mellitus, Renal Impairment","enrollment":62},{"nctId":"NCT04760626","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1085},{"nctId":"NCT07146347","phase":"PHASE1","title":"Comparison Study of Insulin GZR4 With Insulin Degludec","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-08-15","conditions":"Type 2 Diabetes","enrollment":14},{"nctId":"NCT06238778","phase":"PHASE2","title":"Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diasome Pharmaceuticlas, Inc.","startDate":"2024-01-23","conditions":"Diabetes Mellitus, Type 1","enrollment":227},{"nctId":"NCT05463744","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-12","conditions":"Type 1 Diabetes, Diabetes","enrollment":692},{"nctId":"NCT05275400","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-03-08","conditions":"Type 2 Diabetes","enrollment":986},{"nctId":"NCT06288412","phase":"PHASE1","title":"A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-26","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT05362058","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-06-03","conditions":"Diabetes, Type 2 Diabetes","enrollment":928},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT06925334","phase":"PHASE4","title":"A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-05-20","conditions":"Type 2 Diabetic Patients","enrollment":170},{"nctId":"NCT05243628","phase":"PHASE4","title":"Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2022-03-31","conditions":"Type 1 Diabetes","enrollment":33},{"nctId":"NCT04538352","phase":"PHASE4","title":"Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2021-01-18","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT06202079","phase":"PHASE2","title":"A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-08-11","conditions":"Diabetes Mellitus, Type 2","enrollment":179},{"nctId":"NCT06199505","phase":"PHASE2","title":"A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-11-21","conditions":"Type 2 Diabetes","enrollment":153},{"nctId":"NCT05036876","phase":"NA","title":"Degludec Glargine U300 Hospital Study","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2021-10-10","conditions":"Type 2 Diabetes","enrollment":220},{"nctId":"NCT04795531","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-24","conditions":"Diabetes Mellitus, Type 2","enrollment":588},{"nctId":"NCT05218915","phase":"PHASE4","title":"Basal Plus GLP1-ra on Glycemic Variability in CKD","status":"COMPLETED","sponsor":"Elaine Chow","startDate":"2022-01-28","conditions":"Diabetes Mellitus, Diabetic Kidney Disease","enrollment":95},{"nctId":"NCT04042441","phase":"","title":"A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-07-29","conditions":"Diabetes Mellitus, Type 2","enrollment":1122},{"nctId":"NCT06559722","phase":"PHASE3","title":"A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-08","conditions":"Type 2 Diabetes","enrollment":510},{"nctId":"NCT06556641","phase":"PHASE1","title":"A Clinical Study of GZR33 and GZR101 in Healthy Subjects","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2022-12-17","conditions":"Healthy Subjects","enrollment":28},{"nctId":"NCT06553248","phase":"PHASE1","title":"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-03-22","conditions":"Diabetes","enrollment":36},{"nctId":"NCT05904743","phase":"PHASE4","title":"INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2023-07-07","conditions":"Diabetes Mellitus, Type 1","enrollment":141},{"nctId":"NCT06178874","phase":"NA","title":"Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-12-01","conditions":"Glycemic Control, Insulin, Critical Illness","enrollment":90},{"nctId":"NCT06132126","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-11-17","conditions":"Healthy, Type 2 Diabetes Mellitus","enrollment":66},{"nctId":"NCT05221580","phase":"","title":"China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-18","conditions":"Diabetes Mellitus, Type 2","enrollment":887},{"nctId":"NCT06056167","phase":"NA","title":"Degludec Insulin Use in Critically Ill Patients","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2023-05-17","conditions":"Diabetes Mellitus, Critical Illness, Hyperglycemia","enrollment":155},{"nctId":"NCT06449703","phase":"PHASE1","title":"A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects","status":"RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-05-06","conditions":"Healthy","enrollment":44},{"nctId":"NCT06408532","phase":"PHASE4","title":"The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-04-30","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT04666987","phase":"","title":"A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-21","conditions":"Diabetes Mellitus, Type 2","enrollment":359},{"nctId":"NCT04227431","phase":"","title":"A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-17","conditions":"Diabetes Mellitus, Type 2","enrollment":938},{"nctId":"NCT04623086","phase":"PHASE4","title":"Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-02-14","conditions":"Type 1 Diabetes","enrollment":59},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT03862716","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":159},{"nctId":"NCT06057077","phase":"PHASE1, PHASE2","title":"Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus","status":"UNKNOWN","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2024-01-01","conditions":"Type 1 Diabetes","enrollment":120},{"nctId":"NCT03737240","phase":"PHASE3","title":"IDegLira HIGH Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-01-15","conditions":"Diabetes Mellitus","enrollment":145},{"nctId":"NCT04569994","phase":"PHASE1","title":"A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-09-30","conditions":"Healthy Volunteers, Diabetes Mellitus, Type 1","enrollment":68},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05802862","phase":"PHASE3","title":"A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China","status":"UNKNOWN","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2023-05-01","conditions":"Diabetes","enrollment":408},{"nctId":"NCT03387787","phase":"PHASE2, PHASE3","title":"Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-01-30","conditions":"Type 2 Diabetes Mellitus","enrollment":15},{"nctId":"NCT05767255","phase":"PHASE3","title":"Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue","status":"UNKNOWN","sponsor":"Hospital Universitario San Ignacio","startDate":"2022-12-01","conditions":"Diabetes Mellitus, Type 2 Treated With Insulin","enrollment":66},{"nctId":"NCT04671043","phase":"NA","title":"Caffeine Ingestion to Counter the Exercise-mediated Fall in Glycaemia in Type 1 Diabetes","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2022-02-04","conditions":"Caffeine and Carbohydrate, Carbohydrate Only, Placebo","enrollment":21},{"nctId":"NCT03952130","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-29","conditions":"Type 1 Diabetes Mellitus","enrollment":354},{"nctId":"NCT03377699","phase":"PHASE3","title":"Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-22","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":225},{"nctId":"NCT04663282","phase":"PHASE2","title":"A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-02-04","conditions":"Type 2 Diabetes","enrollment":179},{"nctId":"NCT05434559","phase":"","title":"Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec","status":"COMPLETED","sponsor":"prof dr Pieter Gillard","startDate":"2022-02-20","conditions":"Type 1 Diabetes","enrollment":475},{"nctId":"NCT03172494","phase":"PHASE3","title":"A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":720},{"nctId":"NCT05641337","phase":"PHASE3","title":"Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2022-10-01","conditions":"Liver Cirrhosis, Diabetes","enrollment":184},{"nctId":"NCT04075513","phase":"PHASE4","title":"Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-09","conditions":"Type 1 Diabetes Mellitus","enrollment":343},{"nctId":"NCT04892069","phase":"","title":"Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-27","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT04450394","phase":"PHASE2","title":"A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-07-01","conditions":"Type 2 Diabetes Mellitus","enrollment":278},{"nctId":"NCT05479591","phase":"","title":"A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2022-07-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT03668808","phase":"PHASE4","title":"Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2018-11-16","conditions":"Diabetes Mellitus, Type 1","enrollment":25},{"nctId":"NCT04450407","phase":"PHASE2","title":"A Study of LY3209590 in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-07-06","conditions":"Type 1 Diabetes Mellitus","enrollment":266},{"nctId":"NCT05576298","phase":"PHASE1","title":"A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-10-08","conditions":"Type 2 Diabetes","enrollment":46},{"nctId":"NCT05545800","phase":"PHASE3","title":"Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":78},{"nctId":"NCT05429359","phase":"NA","title":"cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2022-10-01","conditions":"Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT03557892","phase":"NA","title":"Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2018-04-01","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT04585776","phase":"PHASE2","title":"A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-30","conditions":"Type 1 Diabetes","enrollment":31},{"nctId":"NCT02967224","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulins in Insulin Naïve Patients Initiating Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-05","conditions":"Diabetes Mellitus, Type 2","enrollment":705},{"nctId":"NCT02967211","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulin in Patients Already Using Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-12-21","conditions":"Diabetes Mellitus, Type 2","enrollment":609},{"nctId":"NCT03336528","phase":"PHASE4","title":"Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-01-02","conditions":"Type 2 Diabetes","enrollment":180},{"nctId":"NCT05261997","phase":"NA","title":"Endotherapy for Painless Chronic Pancreatitis","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2022-03","conditions":"Pancreatitis, Chronic, Exocrine Pancreatic Insufficiency, Abdominal Pain","enrollment":60},{"nctId":"NCT03952143","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-27","conditions":"Type 2 Diabetes Mellitus","enrollment":628},{"nctId":"NCT03740919","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-07","conditions":"Type 1 Diabetes Mellitus","enrollment":751},{"nctId":"NCT03882970","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1444},{"nctId":"NCT03268005","phase":"PHASE3","title":"Research Study Comparing a New Medicine \"Fast-acting Insulin Aspart\" to Another Already Available Medicine \"NovoRapid\"/\"NovoLog\" in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-09-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1264},{"nctId":"NCT03078478","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1609},{"nctId":"NCT03328845","phase":"PHASE4","title":"Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2017-01-20","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT03416855","phase":"","title":"A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-01-31","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":768},{"nctId":"NCT03400501","phase":"EARLY_PHASE1","title":"Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-10-01","conditions":"Type 1 Diabetes Mellitus","enrollment":32},{"nctId":"NCT04656106","phase":"","title":"A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-27","conditions":"Diabetes Mellitus, Type 2","enrollment":200},{"nctId":"NCT03823339","phase":"","title":"A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-29","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT04955834","phase":"PHASE3","title":"A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-07-27","conditions":"Type 2 Diabetes","enrollment":344},{"nctId":"NCT03987191","phase":"PHASE4","title":"Insulin Pump to Multiple Daily Injection Transition Clinical Trial","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-10","conditions":"Type 1 Diabetes","enrollment":38},{"nctId":"NCT02964104","phase":"PHASE1","title":"A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-11-15","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT04315688","phase":"","title":"A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-03-30","conditions":"Diabetes Mellitus, Type 2","enrollment":494},{"nctId":"NCT04190160","phase":"NA","title":"Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)","status":"COMPLETED","sponsor":"Stefano Rizza","startDate":"2018-11-19","conditions":"Type2 Diabetes","enrollment":35},{"nctId":"NCT04965051","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-08","conditions":"Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":278,"reaction":"NAUSEA"},{"count":258,"reaction":"VOMITING"},{"count":223,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":222,"reaction":"OFF LABEL USE"},{"count":210,"reaction":"STRESS"},{"count":208,"reaction":"ABDOMINAL PAIN"},{"count":199,"reaction":"ASCITES"},{"count":199,"reaction":"HYPONATRAEMIA"},{"count":194,"reaction":"SEPSIS"},{"count":192,"reaction":"CONSTIPATION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20180809","type":"SUPPL","sponsor":"NOVO","applicationNumber":"BLA203314"},{"date":"20161216","type":"SUPPL","sponsor":"NOVO","applicationNumber":"BLA203314"},{"date":"20220701","type":"SUPPL","sponsor":"NOVO","applicationNumber":"BLA203314"},{"date":"20191115","type":"SUPPL","sponsor":"NOVO","applicationNumber":"BLA203314"},{"date":"20150925","type":"ORIG","sponsor":"NOVO","applicationNumber":"BLA203314"},{"date":"20220701","type":"SUPPL","sponsor":"NOVO","applicationNumber":"BLA203314"},{"date":"20181121","type":"SUPPL","sponsor":"NOVO","applicationNumber":"BLA203314"},{"date":"20180326","type":"SUPPL","sponsor":"NOVO","applicationNumber":"BLA203314"},{"date":"20160624","type":"SUPPL","sponsor":"NOVO","applicationNumber":"BLA203314"},{"date":"20160708","type":"SUPPL","sponsor":"NOVO","applicationNumber":"BLA203314"},{"date":"20191115","type":"SUPPL","sponsor":"NOVO","applicationNumber":"BLA203314"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Degludec","genericName":"Degludec","companyName":"University of Split, School of Medicine","companyId":"university-of-split-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}